Last reviewed · How we verify

NCT05742282: ASPIRE

ASPIRE (Aub-haS2 Plus bIomaRkErs)

Not yet recruiting Last updated 20 May 2025
What this trial tests

trial in Perioperative Medicine in 2,500 participants. Not yet recruiting.

Timeline
21 June 2025
Primary endpoint
30 September 2026
30 October 2026

Quick facts

Lead sponsorHospital Samaritano Paulista
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment2,500
Start date21 June 2025
Primary completion30 September 2026
Estimated completion30 October 2026
Sites1 location across Brazil

Conditions studied

Sponsor

Hospital Samaritano Paulista

Who can join

40 and older, any sex, with Perioperative Medicine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ASPIRE is a prospective, multicenter, observational study that will assess the performance of AUB-HAS2 to predict the occurrence of major adverse cardiovascular events 30-days after a non-cardiac surgery and the additional role of high-sensitivity troponin T and NT-ProBNP biomarkers in the accuracy of different event prediction indexes after non-cardiac procedures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Perioperative Medicine

Currently open trials in the same condition.

Other Hospital Samaritano Paulista trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05742282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing